Cost-effectiveness of HerzMobil Tirol, a multidimensional post-discharge disease management program for heart failure patients Economic evaluation along a one-year observation period

G Poelzl,T Egelseer-Bruendl,B Jahn,M Arvandi,S Puntscher,J Santamaria-Navarro,B Pfeifer,C Rissbacher,R Modre-Osprian,U Siebert
DOI: https://doi.org/10.1093/eurheartj/ehad655.1051
IF: 39.3
2023-11-01
European Heart Journal
Abstract:Abstract Methods We conducted a cost-effectiveness analysis along a retrospective cohort study of the routine DMP in the province of Tyrol, Austria (HerzMobil Tirol, DMP-HMT) with a propensity score matched cohort of 257 individuals in the usual care (UC) and 251 in the DMP group and a one-year follow up (2016-2019). We determined the effectiveness (hospital-free life expectancy, event-free life years and life years gained, and number of avoided rehospitalizations), costs (DMP, rehospitalizations) and the incremental cost-effectiveness ratio (ICER) of DMP-HMT vs. UC. Data preparation included two steps, missing value imputation and adjustment for remaining confounding due to imperfect matching. We performed a nonparametric sensitivity analysis with bootstrap sampling (n=5,000 replications), sensitivity analyses on costs of HF-rehospitalizations after events that are highly irrelevant for the stated research question and on costs per disease-related diagnosis (DRG) score for rehospitalizations. Results The base-case analysis showed that, on average, DMP-HMT results in 42 additional hospital-free life days, 0.54 event-free days to the next cardiovascular event, 40 additional life days, and 0.12 avoided hospitalizations per person compared to UC. The average DPM costs are EUR 1,916 per person. Mean rehospitalization costs are EUR 5,551 in HMT and EUR 6,943 in UC. The ICER of DMP-HMT compared to UC is EUR 4,773 per life-year gained outside the hospital. In a sensitivity analysis, DMP-HMT was also cost saving when "high irrelevant costs" related to the DMP were replaced with average costs. The ICER decreases with increasing costs per DRG score. Conclusions Our economic evaluation along the cohort study showed that the DMP HerzMobil Tirol is cost-effective compared to UC based on the one-year time follow up horizon. The DMP was cost-saving in a sensitivity analysis correcting for "high irrelevant costs". Our findings promote widespread adoption of telemedicine assisted DMP for HF. Further research is needed on the long-term assessment of benefits and costs beyond the study period using a decision-analytic model and considering upcoming real-world evidence.
cardiac & cardiovascular systems
What problem does this paper attempt to address?